Javascript must be enabled to continue!
Orthostatic Hypotension and Therapy with an Ace Inhibitor in Hypertensive Patients
View through CrossRef
Abstract
Orthostatic hypotension (OH) is defined as a drop in the systolic blood pressure greater than 20 mmHg and that of the diastolic blood pressure greater than 10 mmHg within 3 minutes from the change of the body’s position from lying or sitting down to standing up. The objective of this study is to analyse the incidence and severity of orthostatic hypertension when taking one of the generic representatives of the ACE inhibitor group (trandolapril) as a monotherapy in patients with essential hypertension. Th e study involved 314 patients (medium age of 54±4 years; 52.5% men) with poorly regulated hypertension for whom trandolapril was introduced as monotherapy. Th e incidence rates of patients with and without orthostatic hypotension between the first and second examination were not statistically significantly different. At the second control examination, 7 patients (2,3%) still had orthostatic hypotension, as was the case at the first examination. Between the third and fourth controls, a statistically significant decrease in the number of patients with orthostatic hypotension was recorded. No statistically significant difference in the incidence of orthostatic hypotension between patients with normal body mass and those who were overweight was observed. Our study has shown that certain ACE inhibitors, such as Trandolapril, do not have a pronounced adverse effect with regard to orthostatic hypotension and that in long-term application, they can have a positive role in the prevention of hypotensive episodes and improving patient compliance.
Title: Orthostatic Hypotension and Therapy with an Ace Inhibitor in Hypertensive Patients
Description:
Abstract
Orthostatic hypotension (OH) is defined as a drop in the systolic blood pressure greater than 20 mmHg and that of the diastolic blood pressure greater than 10 mmHg within 3 minutes from the change of the body’s position from lying or sitting down to standing up.
The objective of this study is to analyse the incidence and severity of orthostatic hypertension when taking one of the generic representatives of the ACE inhibitor group (trandolapril) as a monotherapy in patients with essential hypertension.
Th e study involved 314 patients (medium age of 54±4 years; 52.
5% men) with poorly regulated hypertension for whom trandolapril was introduced as monotherapy.
Th e incidence rates of patients with and without orthostatic hypotension between the first and second examination were not statistically significantly different.
At the second control examination, 7 patients (2,3%) still had orthostatic hypotension, as was the case at the first examination.
Between the third and fourth controls, a statistically significant decrease in the number of patients with orthostatic hypotension was recorded.
No statistically significant difference in the incidence of orthostatic hypotension between patients with normal body mass and those who were overweight was observed.
Our study has shown that certain ACE inhibitors, such as Trandolapril, do not have a pronounced adverse effect with regard to orthostatic hypotension and that in long-term application, they can have a positive role in the prevention of hypotensive episodes and improving patient compliance.
Related Results
Dual Inhibition of Neutral Endopeptidase and Angiotensin-Converting Enzyme in Rats With Hypertension and Diabetes Mellitus
Dual Inhibition of Neutral Endopeptidase and Angiotensin-Converting Enzyme in Rats With Hypertension and Diabetes Mellitus
Abstract—It has been suggested that combined inhibition of angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) may lower blood pressure more effectively than either...
Long-Term Outcomes of Hyperadrenergic Orthostatic Hypotension
Long-Term Outcomes of Hyperadrenergic Orthostatic Hypotension
Abstract
Purpose
Hyperadrenergic orthostatic hypotension is a subtype of orthostatic hypotension associated with elevated norepinephrine levels upon standing. Our previous...
Orthostatic hypotension and mortality risk in geriatric outpatients: the impact of duration and magnitude of the blood pressure drop
Orthostatic hypotension and mortality risk in geriatric outpatients: the impact of duration and magnitude of the blood pressure drop
Introduction:
Orthostatic hypotension is a common condition associated with an increased mortality risk. This study investigates this association specifically in geriat...
e0157 RNA interference targeting ACE and AT1R gene reduced blood pressure and improved myocardial remodelling in SHR
e0157 RNA interference targeting ACE and AT1R gene reduced blood pressure and improved myocardial remodelling in SHR
Introduction
Angiotensin-converting enzyme (ACE) and angiotensin II (Ang II) Type 1 receptor (ATlR) have been shown to play an important role in the pathogenesis ...
Vertigo and nystagmus in orthostatic hypotension
Vertigo and nystagmus in orthostatic hypotension
Background and purposeGeneralized cerebral ischaemia from cardiovascular dysfunction usually leads to presyncopal dizziness, but several studies reported a higher frequency of rota...
Haemodynamic Characteristics And Factors Influencing The Head-Up Tilt Test In Patients With Orthostatic Hypotension
Haemodynamic Characteristics And Factors Influencing The Head-Up Tilt Test In Patients With Orthostatic Hypotension
Abstract
Background: Failure to activate autonomic neural and hormonal reflex mechanisms could result in orthostatic hypotension. Patients with orthostatic hypotension ofte...
An analysis of the orthostatic blood pressure changes in cancer patients
An analysis of the orthostatic blood pressure changes in cancer patients
Abstract
Background/Introduction
The autonomic nervous system plays a crucial role in orthostatic blood pressure (BP) changes, i...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

